Cell Line Development, Manufacturing Services and License AgreementCell Line Development, Manufacturing Services and License Agreement • June 27th, 2024 • Eliem Therapeutics, Inc. • Pharmaceutical preparations
This Cell Line Development, Manufacturing Services and License Agreement is entered into as of February 9th, 2021 (“Effective Date”) between:
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTSAcquisition Agreement • June 27th, 2024 • Eliem Therapeutics, Inc. • Pharmaceutical preparations
The unaudited pro forma condensed combined financial information was prepared on the basis that the Acquisition is accounted for as an asset acquisition of Tenet by Eliem under accounting principles generally accepted in the United States. In accordance with the Financial Accounting Standards Board’s Accounting Standards Codification (“ASC”) Topic 805, Business Combinations, Eliem first evaluated the initial screen test to determine if substantially all of the fair value of the gross assets acquired of Tenet is concentrated in a single asset or a group of similar assets. Eliem concluded that substantially all of the fair value of the gross assets being acquired of Tenet is concentrated in the TNT119 (“IPR&D”) asset. Accordingly, Eliem will account for the transaction as an asset acquisition. Under the asset acquisition method of accounting, consideration is allocated to the assets acquired and liabilities assumed on a relative fair value basis, no goodwill is recorded and all direct ac
ASSET PURCHASE AGREEMENT BETWEEN ACELYRIN, INC., WH2, LLC AND TENET MEDICINES, INC. DATED AS OF January 4, 2024Asset Purchase Agreement • June 27th, 2024 • Eliem Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS ASSET PURCHASE AGREEMENT (this “Agreement”), dated as of January 4, 2024, is made by and between Tenet Medicines, Inc., a Delaware corporation (“Buyer”), ACELYRIN, INC., a Delaware corporation (“Parent”), and WH2, LLC, a Delaware limited liability company and wholly-owned subsidiary of Parent (“WH2”, and together with Parent, “Seller”).
1) CANCER RESEARCH TECHNOLOGY LIMITED AND (2) TENET MEDICINES, INC. AMENDED AND RESTATED LICENCE AGREEMENTLicence Agreement • June 27th, 2024 • Eliem Therapeutics, Inc. • Pharmaceutical preparations
